All
Maintenance Rubraca Has Potential in Ovarian Cancer
July 9th 2017For women with platinum-sensitive, high-grade ovarian, fallopian tube or primary peritoneal cancer, an improved progression-free survival (PFS) was seen for those who took Rubraca (rucaparib) as a maintenance therapy, compared to placebo, according to the phase 3 ARIEL3 trial.
Examining the Role of Blood-Based Biomarkers in Lung Cancer
July 6th 2017Blood-based biomarkers are moving into the realm of non-small cell lung cancer (NSCLC), and while tissue biopsies are still the standard, if plasma assays are positive, they can be helpful in deciding the first-line treatment that patients should receive.
Putting It on Paper: Patient Writing Program Encourages Expression During the Cancer Journey
July 5th 2017Every fall, Visible Ink has a call for submissions, and from hundreds, a selection committee chooses no more than 15 to be performed “by amazing people, mostly from Broadway, who come in and do this pro bono,” explains writer Judith Kelman, who leads Visible Ink. The performers are actors, singers and dancers, including Tony Award winners.
FDA Approves Tool for Blood Cancer Detection
June 30th 2017ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.
Using Playtime to Avoid Anesthesia in Children With Cancer
June 29th 2017When pediatric patients are given radiation treatment for cancer, they often get scared or nervous because they do not have an understanding of the process and the machines involved. To remedy this, anesthesia is used in many cases, though the long-term side effects are still unknown.